Bluejay Diagnostics Reports $7.38 Million in Cash and Advances Clinical Milestones

Bluejay Diagnostics reported $7.38M in cash as of Q3 2026, up from $5.16M at year-end 2025. The company completed SYMON-II study enrollment and advanced Symphony platform manufacturing. It aims for FDA 510(k) submission in H1 2027, contingent on validation. Current funds should last until Q2 2027, with additional financing needed for long-term plans.

Original reporting
Published Nov 13, 2026, 9:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Bluejay Diagnostics Reports $7.38 Million in Cash and Advances Clinical Milestones — source image
Decision brief

The 30-second read

$BJDXBearishLow
01

Why it matters

The disclosed cash runway to Q2 2027 and need for additional financing suggest short‑term downside risk, while trial progress could be a catalyst if FDA clearance is achieved.

02

Market read

Micro‑cap news with modest immediate market relevance; investors will watch for financing updates and FDA filing outcomes.

03

What to watch

Potential government contract via Lovell Government Services and manufacturing partnership with Sanyoseiko may improve future cash flow.

Relevance 7/10Novelty 7/10Timing: after filing release

Background

Bluejay Diagnostics is a micro‑cap biotech developing an IL‑6 sepsis test. The filing reports cash levels and trial enrollment milestones.

Company-level read

Ticker impact

$BJDXBearishMedium confidence
Context

Bluejay Diagnostics disclosed $7.38M cash and completed SYMON-II enrollment, indicating runway to Q2 2027 and upcoming FDA 510(k) filing.

Expected impact

likely pressure as investors weigh cash constraints and need for additional financing

Evidence & confidence

Micro‑cap with modest cash runway; no new financing announced, so market may discount the stock until funding is secured.

Market effects

Provides a data point on early‑stage sepsis diagnostics market but unlikely to shift sector sentiment.

Limited to U.S. biotech investors; no broader regional effect.

Minimal global impact given the company's size and niche focus.

Counterpoint

If the company secures a strategic partnership or financing soon, the cash runway could be less of a concern.

Key entities

  • Bluejay Diagnostics, Inc.

    Developer of the Symphony IL‑6 sepsis diagnostic platform.

  • Toray Industries

    Contractual partner for cartridge manufacturing deadline.

Related articles

$BJDXMed

Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update Completes SYMON-II clinical study enrollment and advances clinical validation activities Achieves critical manufacturing milestone ahead of contractual deadline, strengtheni

$BJDXMedAI 8/10

Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 For Immediate Release Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock. SYMON-II Clinical Validation Dataset Represents a Key Milestone as Bluejay Advances the Symphony™ IL-6 Test Towar

$BJDXMedAI 8/10

Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock

Bluejay Diagnostics (NASDAQ:BJDX) announced baseline clinical data from its SYMON-II study, evaluating IL-6 as a biomarker for 28-day mortality risk in sepsis patients. The study included 777 patients, with an 18% mortality rate. The company aims to use this data to support a regulatory submission for its Symphony IL-6 Test, which is not yet FDA-approved.